Article
Immunology
Mathieu Ferrari, Shimobi C. Onuoha, Liliane Fossati-Jimack, Alessandra Nerviani, Pedro L. Alves, Sara Pagani, Cecilia Deantonio, Federico Colombo, Claudio Santoro, Daniele Sblattero, Costantino Pitzalis
Summary: Novel tissue-specific agent BsAb shows improved therapeutic effect by targeting the arthritic synovium, providing better efficacy compared to standard treatment.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Haroutyun Joulfayan, Tigran Makunts, Ruben Abagyan
Summary: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 1% of the global population. The use of TNF inhibitors for RA treatment may lead to adverse events, such as the onset of psoriasis. This study analyzed a large number of safety reports and provided evidence for a significant association between TNF inhibitor use and psoriasis, with varying degrees of association observed among different drugs.
SCIENTIFIC REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Tomasz Wysocki, Agnieszka Paradowska-Gorycka
Summary: Rheumatoid arthritis is a common inflammatory arthritis in which tumor necrosis factor plays a key role. However, there is variation in response to TNF-targeting drugs, which may be influenced by genetic factors. The field of pharmacogenomics offers potential for developing novel prognostic tools.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Orthopedics
Antonio Julia, Maria Lopez-Lasanta, Francisco Blanco, Antonio Gomez, Isabel Haro, Antonio Juan Mas, Alba Erra, Ma Luz Garcia Vivar, Jordi Monfort, Simon Sanchez-Fernandez, Isidoro Gonzalez, Mercedes Alperi, Raul Castellanos-Moreira, Antonio Fernandez-Nebro, Cesar Diaz-Torne, Nuria Palau, Raquel Lastra, Jordi Llados, Raimon Sanmarti, Sara Marsal
Summary: This study revealed significant antibody interactions, including the interaction between anti-CarP and anti-PAD4, as well as between anti-CCP and RF, which are associated with treatment response in RA patients receiving anti-TNF therapy.
BMC MUSCULOSKELETAL DISORDERS
(2021)
Article
Medicine, General & Internal
Daniela Anghel, Carmen Adella Sirbu, Oana-Georgiana Petrache, Daniela Opris-Belinski, Maria Magdalena Negru, Violeta-Claudia Bojinca, Cristina Florentina Plesa, Florentina Ionita Radu
Summary: Videocapillaroscopy is a simple, non-invasive investigation used to study nailfold capillaries. It is commonly used for patients with Raynaud's phenomenon and systemic sclerosis, but can also be used for patients with suspected microcirculation alterations. The study aimed to identify nailfold videocapillaroscopic abnormalities in rheumatoid arthritis and psoriatic arthritis patients and analyze their correlation with 12 months of anti-TNF-α therapy. The findings showed significant improvements in capillary density, dilated and giant capillaries, elongated capillaries, and angiogenesis after 12 months of treatment, with no avascular areas found.
Article
Pharmacology & Pharmacy
Alexander Vugler, James O'Connell, Mai Anh Nguyen, Dietmar Weitz, Thomas Leeuw, Elizabeth Hickford, Alexander Verbitsky, Xiaoyou Ying, Markus Rehberg, Bruce Carrington, Mark Merriman, Andrew Moss, Jean-Marie Nicholas, Phil Stanley, Sara Wright, Tim Bourne, Yann Foricher, Daniel Brookings, Helen Horsley, Matthias Herrmann, Srinivas Rao, Markus Kohlmann, Peter Florian
Summary: This article reports the discovery and development of a potent small molecule inhibitor of TNF, SAR441566, which has shown potential as a treatment option for chronic autoimmune diseases. By stabilizing an asymmetrical form of TNF and compromising its functions, SAR441566 offers a promising alternative to established biologic drugs targeting TNF.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Ju Li, Zhongyuan Zhang, Xinhua Wu, Jie Zhou, Deqian Meng, Ping Zhu
Summary: This meta-analysis found that treatment with anti-TNF alpha agents may increase the risk of infectious adverse events while the risk of tuberculosis was not significantly different. The use of anti-TNF agents should be carefully considered based on the risk-benefit ratio suggested by the meta-analysis.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Liana Barenbrug, Maarten te Groen, Frank Hoentjen, Joris van Drongelen, Juul M. P. A. van den Reek, Irma Joosten, Elke M. G. J. de Jong, Renate G. van der Molen
Summary: The use of anti-TNF alpha agents during pregnancy in women with immune mediated inflammatory diseases, such as IBD, RA, and PS, is associated with an increased risk of preterm birth and infections in newborns, particularly for women with IBD. However, there was no increased risk for adverse pregnancy outcomes in women with RA and PS. Vaccination in children exposed to anti-TNF alpha seems to be safe and important in reducing the risk of infections.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Immunology
Jing-Wen Chen, Guo-Shu Deng, Wen-Shuang Zhang, Ming-Ying Zhang, Tong Guan, Qiang Xu
Summary: This study reported the first successful case of a 60-year-old HIV-positive woman with difficult-to-treat RA who was treated with ADA therapy. It was found that adalimumab is a safe option for patients with RA-HIV and may slow down the progression of HIV infection. Furthermore, HAART therapy has the potential to reduce joint pain and fatigue in patients with difficult-to-treat RA.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Jose Manuel Sanchez-Maldonado, Rafael Caliz, Miguel Angel Lopez-Nevot, Antonio Jose Cabrera-Serrano, Ana Moniz-Diez, Helena Canhao, Rob Ter Horst, Luca Quartuccio, Signe B. Sorensen, Bente Glintborg, Merete L. Hetland, Ileana Filipescu, Eva Perez-Pampin, Pablo Conesa-Zamora, Jerzy Swierkot, Alfons A. den Broeder, Salvatore De Vita, Eva Rabing Brix Petersen, Yang Li, Miguel A. Ferrer, Alejandro Escudero, Mihai G. Netea, Marieke J. H. Coenen, Vibeke Andersen, Joao E. Fonseca, Manuel Jurado, Katarzyna Bogunia-Kubik, Eduardo Collantes, Juan Sainz
Summary: This study confirmed the influence of the LINC02549 and LRRC55 loci on determining the response to TNFi in RA patients, while suggesting a weak effect of the MAFB and CNTN5 loci that require further investigation.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Yoonsung Song, Sungsin Jo, Jee Young Chung, Younseo Oh, Subin Yoon, Young Lim Lee, Seong Su Kim, Jae-Hyuk Yang, Kiseok Jang, Chul-Su Yang, Tae-Hwan Kim, Yong-Hee Kim
Summary: A novel strategy was developed to down-regulate TNF-alpha level by suppressing TNF-alpha converting enzyme, offering a potential alternative therapeutic for RA treatment for patients who do not respond to anti-TNF-alpha therapy. This targeted RNA interference system showed enhanced anti-inflammatory and anti-osteoclastogenic effects in arthritis models and human primary cells, indicating its effectiveness as a new treatment approach.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Biochemistry & Molecular Biology
Tatyana P. Makalish, Ilya O. Golovkin, Volodymyr V. Oberemok, Kateryna V. Laikova, Zenure Z. Temirova, Olesya A. Serdyukova, Ilya A. Novikov, Roman A. Rosovskyi, Andrey I. Gordienko, Evgeniya Yu. Zyablitskaya, Elvina A. Gafarova, Kseniya A. Yurchenko, Iryna I. Fomochkina, Anatoly V. Kubyshkin
Summary: The study demonstrates the potential of Cytos-11 antisense oligonucleotide in treating rheumatoid arthritis by effectively suppressing TNF-alpha gene expression, reducing joint inflammation, and inhibiting pannus development, showing comparable results to adalimumab.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Medicine, General & Internal
Boglarka Soos, Miklos Fagyas, Agnes Horvath, Edit Vegh, Anita Pusztai, Monika Czokolyova, Alexandra Csongradi, Attila Hamar, Zsofia Petho, Nora Bodnar, Gyoergy Kerekes, Katalin Hodosi, Eva Szekanecz, Szilvia Szamosi, Sandor Szanto, Gabriella Szucs, Zoltan Papp, Zoltan Szekanecz
Summary: The study revealed that anti-TNF therapy may increase ACE and ACE2 levels in the sera of RA and AS patients, and these levels are associated with disease duration, markers of inflammation, and vascular pathophysiology. The changes in ACE and ACE2 are influenced by treatment and other factors such as RF or FMD.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
Takeshi Iwasaki, Ryu Watanabe, Hiromu Ito, Takayuki Fujii, Kenji Okuma, Takuma Oku, Yoshitaka Hirayama, Koichiro Ohmura, Koichi Murata, Kosaku Murakami, Hiroyuki Yoshitomi, Masao Tanaka, Shuichi Matsuda, Fumihiko Matsuda, Akio Morinobu, Motomu Hashimoto
Summary: A multi-omics analysis of TNFi responses in a Japanese RA cohort revealed that the dynamics of the type I and II IFN pathways affected long-term responses to TNFi, providing information on its biological background and potential for clinical applications.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jette A. van Lint, Naomi T. Jessurun, Sander W. Tas, Harald E. Vonkeman, Martijn B. A. van Doorn, Frank Hoentjen, Michael T. Nurmohamed, Eugene P. van Puijenbroek, Bart J. F. van den Bemt
Summary: This study describes the pattern and characteristics of fatigue as an adverse drug reaction of biologics in IMID patients, and compares patient and treatment characteristics with patients reporting other ADRs or no ADRs.
Article
Rheumatology
Ennio G. Favalli, Andrea Becciolini, Antonio Carletto, Fabrizio Conti, Giorgio Amato, Enrico Fusaro, Luca Quartuccio, Colin Gerard Egan, Andrea Lo Monaco, Maurizio Benucci, Fausto Salaffi, Angelo Semeraro, Simone Parisi, Fulvia Ceccarelli, Ilaria Piazza, Rosario Foti
RHEUMATOLOGY INTERNATIONAL
(2020)
Review
Immunology
Ennio Giulio Favalli, Marco Matucci-Cerinic, Zoltan Szekanecz
AUTOIMMUNITY REVIEWS
(2020)
Review
Rheumatology
Xenofon Baraliakos, Lianne S. Gensler, Salvatore D'Angelo, Florenzo Iannone, Ennio G. Favalli, Natasha de Peyrecave, Simone E. Auteri, Roberto Caporali
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2020)
Letter
Rheumatology
Ennio Giulio Favalli, Francesca Ingegnoli, Rolando Cimaz, Roberto Caporali
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Letter
Rheumatology
Serena Bugatti, Ludovico De Stefano, Ennio Giulio Favalli, Roberto Caporali, Carlomaurizio Montecucco
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Letter
Rheumatology
Ennio Giulio Favalli, Orazio De Lucia, Martina Biggioggero, Nicoletta Del Papa, Roberto Caporali
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Immunology
Piercarlo Sarzi-Puttini, Daniela Marotto, Roberto Caporali, Carlo Maurizio Montecucco, Ennio Giulio Favalli, Franco Franceschini, Michela Fredi, Silvia Balduzzi, Chiara Bazzani, Sara Bongiovanni, Valeria Giorgi, Alberto Batticciotto, Antonella Cappelli, Patrizia Balzarini, Lorenzo Dagna, Silvia Sartorelli, Viviana Ravagnani, Silvia Tamanini, Sonia Farah, Paola Faggioli, Laura Castelnovo, Alfredo Maria Lurati, Massimo Galli, Fausto Salaffi
Summary: The study found that rheumatic patients have a similar risk of contracting COVID-19 as the general population, but age, disease duration, and number of co-morbidities are associated with an increased risk of a severe form of the disease. Immunosuppressants drugs seem to not effectively represent a risk factor for COVID-19.
JOURNAL OF AUTOIMMUNITY
(2021)
Letter
Rheumatology
Francesca Ingegnoli, Gilberto Cincinelli, Angela Flavia Luppino, Ennio Giulio Favalli, Annalisa Orenti, Patrizia Boracchi, Roberto Caporali
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Review
Immunology
Ennio Giulio Favalli, Gabriella Maioli, Martina Biggioggero, Roberto Caporali
Summary: The COVID-19 pandemic poses challenges for managing patients with rheumatoid arthritis (RA) due to their increased susceptibility to infection events. Disease-modifying anti-rheumatic drugs (DMARDs) have potential effects on patients' vulnerability to COVID-19, and international guidelines emphasize the importance of focusing on RA patients in this context.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Maria Gabriella Raimondo, Martina Biggioggero, Lavinia Agra Coletto, Andreas Ramming, Roberto Caporali, Ennio Giulio Favalli
Summary: Rheumatoid arthritis is a chronic autoimmune disease with a modified natural course due to the development of new therapeutic approaches. Filgotinib, a Janus kinase1 selective inhibitor, has shown comparable clinical efficacy to biologic treatments for active RA with an acceptable safety profile. Real-life data and head-to-head clinical trials are needed to confirm its efficacy and safety.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Article
Rheumatology
Serena Bugatti, Ludovico De Stefano, Bernardo D'Onofrio, Andrea Nicrosini, Eleonora Mauric, Michele di Lernia, Garifallia Sakellariou, Ennio Giulio Favalli, Antonio Manzo, Roberto Caporali, Carlomaurizio Montecucco
Summary: This study found that in the early stages of rheumatoid arthritis, particularly in patients who test positive for autoantibodies, inflammatory markers are directly correlated with the Patient Global Assessment. However, in patients with established rheumatoid arthritis, there is no independent correlation between inflammatory markers and the Patient Global Assessment, regardless of disease activity and autoantibody status.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Pharmacology & Pharmacy
Gabriella Maioli, Roberto Caporali, Ennio Giulio Favalli
Summary: This article discusses the role of the IL-6 pathway in the pathogenesis of rheumatoid arthritis and the pharmacologic properties of the IL-6 inhibitor sarilumab. Clinical trials have confirmed the efficacy and safety of sarilumab in treating RA, making it a potential alternative for patients intolerant to conventional disease-modifying drugs.
EXPERT OPINION ON DRUG DISCOVERY
(2022)
Article
Rheumatology
M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E. G. Favalli, R. Caporali
Summary: The objective of this study was to evaluate the survival rates of biological disease-modifying anti-rheumatic drugs (bDMARDs) in patients with psoriatic arthritis (PsA), comparing tumor necrosis factor inhibitors (TNFi) and non-TNFi retention rates. The study found that the TNFi group had a younger age at the start of therapy and a lower proportion of patients with skin psoriasis. Survival analysis showed no significant differences between TNFi and non-TNFi groups. Cox regression analysis identified fibromyalgia as a predictor of drug failure and first-line bDMARDs as a protective factor.
Article
Rheumatology
Ennio Giulio Favalli, Serena Bugatti, Catherine Klersy, Martina Biggioggero, Silvia Rossi, Orazio De Lucia, Francesca Bobbio-Pallavicini, Antonella Murgo, Silvia Balduzzi, Roberto Caporali, Carlomaurizio Montecucco
ARTHRITIS RESEARCH & THERAPY
(2020)
Article
Rheumatology
E. G. Favalli, F. Conti, C. Selmi, F. Iannone, R. Bucci, F. D'Onofrio, G. Carlino, L. Santo, A. Semeraro, C. Zuccaro, S. D'Angelo, F. Atzeni, F. Marino, S. Monti, G. M. Guidelli, F. R. Spinelli, M. Biggioggero, R. Caporali
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2020)